MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 220991-20-8
MCE 国际站:Lumiracoxib
产品活性:Lumiracoxib 是一种强效、选择性、口服活性 COX-2 抑制剂,Ki 值为 0.06 μM。Lumiracoxib 是一种非选择性非甾体抗炎试剂 (NSAID),具有抗炎、解热活性。Lumiracoxib 可用于骨关节炎和骨癌研究。
研究领域:Immunology/Inflammation
作用靶点:COX
In Vitro: Lumiracoxib inhibits purified COX-1 and COX-2 with Ki values of 3 μM and 0.06 μM, respectively. In cellular assays, Lumiracoxib has an IC50 of 0.14 μM in COX-2-expressing dermal fibroblasts, but causesno inhibition of COX-1 at concentrations up to 30 μM in HEK293 cells transfected with human COX-1.In a human whole blood assay, IC50 values for Lumiracoxib are 0.13 μM for COX-2 and 67 μM for COX-1.
In Vivo: Lumiracoxib (oral administration; 10 and 30 mg/kg; single dose) significantly reverses the established hyperalgesia with a maximal 58% reversal observed 3 h following administration in rat model.Lumiracoxib (oral administration; 10 and 30 mg/kg; twice daily; from day 10 to day 20 following MRMT-1 cell injection) significantly attenuates the weight-bearing difference observed on days 14, 17 and 20. The repeated administration significantly reverses static allodynia measured 90 min following the final administration.It significantly reduces the radiologically observed structural changes 20 days after inoculation of MRMT-1 cells in rat.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Pyroptosis Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Meloxicam-d3-1 | 4-Methylamino antipyrine hydrochloride | Vedaprofen-d3 | Pelubiprofen-13C,d3 | N-tert-Butyl-α-phenylnitrone-d14 | Tepoxalin | Ampyrone | Pectolinarigenin | Ermanin | Aceclofenac-d4 | SC-58125 | Salicylic acid-13C6 | (±)-Naproxen-d3-1 | Dehydroevodiamine hydrochloride | Aspirin-d4 | Asaraldehyde | Broussonin E | (-)-Epicatechin | COX-2/15-LOX-IN-1 | 20(S)-Ginsenoside Rg3 | Ginsenoside Rd | Salicylic acid-d6 | TFAP | Hydrangenol | Alminoprofen | Acetaminophen-d3 | FPL 62064 | Crocin II | AG-024322 | Ketoprofen-13C,d3
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-13507
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。